Quality Risk Management: Degree of formality, Formal and Informal QRM
Abstract
The International Council for Harmonization’s (ICH) Q9 (R1): Quality Risk Management (QRM) guideline made effective from May, 2023. ICH Q9’s revision provides guidance on QRM for the pharmaceutical industry and regulatory environment. It aims to improve decision-making by offering a systematic approach that complements existing quality practices and guidelines. The document emphasizes that understanding formality in quality risk management can optimize resource usage and support risk-based decision-making by reflecting the level of importance, uncertainty, and complexity of the decision.5 QRM is the process of appropriately managing risks to product quality throughout the product's life cycle in order to optimize its benefit–risk balance. It is a systematic process for the assessment, control, communication and review of risks to the quality of the medicinal product. The level of effort, formality and documentation of the quality risk management process should be commensurate with the level of risk. The overall approach for determining how much formality to apply during QRM activities should be described within the quality system. In addition, subjectivity can directly affect the effectiveness of risk management activities and the decisions made. Therefore, it is important that subjectivity is managed and minimized.1,6
Keywords: Quality Risk Management (QRM), Degree of Formality, Uncertainty, Importance, Complexity, Formal risk assessment, Informal risk assessment, QRM Techniques, QRM Tools, ICH
Keywords:
Quality Risk Management (QRM), Degree of Formality, Uncertainty, Importance, Complexity, Formal risk assessmentDOI
https://doi.org/10.22270/jddt.v15i2.6978References
1. ICH Q9(R1): Quality Risk Management; International Conference on Harmonization: 2023
2. Q9 (R1) Quality Risk Management, USFDA: 2023.
3. EMA (European Medicines Agency) Quality Risk Management ICH Q9 (R1), 2023.
4. Ghada Haddad and Darshana Patel, Navigating the Formality Spectrum in ICH Q9(R1), Journal: Pharmaceutical Technology, July 2023, Volume 47, Issue 7.
5. Stacey Largent and Virginia Andreotti-Jones, ValSource Inc., ICH Guideline Q9(R1) on QRM, Part 1: Formality & Risk-Based Decisions, Guest Column, February 28, 2023.
6. Danica Brown and Theo Zacharatos, ValSource Inc., ICH Guideline Q9(R1) on QRM, Part 2: Subjectivity & Supply Continuity, Guest Column, March 7, 2023.
Published



How to Cite
Issue
Section
Copyright (c) 2025 Manish

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).